We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.82B
AUM Growth
+$974M
Cap. Flow
+$85.6M
Cap. Flow %
0.97%
Top 10 Hldgs %
37.09%
Holding
149
New
20
Increased
26
Reduced
29
Closed
13

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$111M
2
AGN.PRA
Allergan plc
AGN.PRA
+$73.1M
3
MRK icon
Merck
MRK
+$69.9M
4
AET
Aetna Inc
AET
+$63.6M
5
VTRS icon
Viatris
VTRS
+$52.4M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$148M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$72.3M
3
AGN
Allergan plc
AGN
+$68.1M
4
ISRG icon
Intuitive Surgical
ISRG
+$67.6M
5
SHPG
Shire pic
SHPG
+$53.4M

Sector Composition

Rank Sector Weight
1 Healthcare 92.96%
2 Financials 2.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EHTH icon
76
eHealth
EHTH
$43.5M
$21.9M 0.25%
1,820,000
– –
NBRV
77
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$20.1M 0.23%
6,712
– –
XNCR icon
78
Xencor
XNCR
$1.47B
$20.1M 0.23%
840,237
– –
NBIX icon
79
Neurocrine Biosciences
NBIX
$18.2B
$19.1M 0.22%
441,341
-1,687,433
-79% -$72.3M
PVLA
80
Palvella Therapeutics
PVLA
$2.04B
$18.9M 0.21%
90,745
– –
DBVT
81
DBV Technologies
DBVT
$806M
$18.1M 0.2%
51,290
+16,720
+48% +$5.87M
STDY
82
DELISTED
SteadyMed Ltd
STDY
$17.8M 0.2%
3,072,196
– –
SVA
83
DELISTED
Sinovac Biotech, Ltd
SVA
$15.3M 0.17%
2,667,500
– –
BCR
84
DELISTED
CR Bard Inc.
BCR
$14.4M 0.16%
58,000
– –
EXAS
85
DELISTED
Exact Sciences
EXAS
$14.2M 0.16%
602,900
-347,100
-37% -$6.88M
TEVA icon
86
Teva Pharmaceuticals
TEVA
$40B
$13.2M 0.15%
412,600
-201,900
-33% -$6.89M
AUPH icon
87
Aurinia Pharmaceuticals
AUPH
$1.92B
$13.2M 0.15%
+1,797,400
New +$8.3M
PRQR icon
88
ProQR Therapeutics
PRQR
$246M
$11.5M 0.13%
2,305,446
– –
NTRA icon
89
Natera
NTRA
$36B
$11.3M 0.13%
1,276,190
– –
SYRE icon
90
Spyre Therapeutics
SYRE
$8.51B
$10.9M 0.12%
58,781
+4,372
+8% +$617K
BMY icon
91
PUT
Bristol-Myers Squibb
BMY
$130B
$10.9M 0.12%
+200,000
New +$11M
WMGIZ
92
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
$10.6M 0.12%
+6,900,000
New +$10.5M
ADAP
93
DELISTED
Adaptimmune Therapeutics
ADAP
$10.6M 0.12%
1,914,660
+1,190,476
+164% +$5.21M
INFI
94
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$10.5M 0.12%
3,250,300
– –
LAB icon
95
Standard BioTools
LAB
$318M
$9.94M 0.11%
1,746,100
– –
HRTX icon
96
Heron Therapeutics
HRTX
$93.2M
$9.75M 0.11%
+650,000
New +$9M
DMTX
97
DELISTED
Dimension Therapeutics, Inc
DMTX
$9.45M 0.11%
5,397,698
– –
NUVA
98
DELISTED
NuVasive, Inc.
NUVA
$9.22M 0.1%
123,500
– –
ALKS icon
99
Alkermes
ALKS
$8.31B
$8.48M 0.1%
+145,000
New +$8.22M
CLLS
100
Cellectis
CLLS
$283M
$8.4M 0.1%
350,000
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2017 Portfolio in Review

As of Q1 2017, OrbiMed held 149 positions worth $8.82B, up 12% from $7.85B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed's Q1 2017 filing shows 20 new, 26 increased, 29 reduced and 13 closed positions. Its largest new stake was Centene: 3,311,400 shares worth $118M. The largest sale was Amgen, an estimated $148M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q1 2017 buy was Centene: 3,311,400 shares worth $118M.
  • OrbiMed added most to Merck in Q1 2017, an estimated $69.9M increase.
  • OrbiMed's biggest Q1 2017 reduction was Amgen, cutting an estimated $148M.
  • OrbiMed fully exited Molina Healthcare in Q1 2017, selling an estimated $26.9M.
  • OrbiMed's ten largest holdings make up 37% of its $8.82B portfolio in Q1 2017.
  • OrbiMed opened 20 new positions and closed 13 in Q1 2017.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $8.82B.

Based on OrbiMed's 13F filing for Q1 2017, filed 15 May 2017.